Greenwich LifeSciences Inc. (GLSI): Market Capitalization-to-Revenue Ratio

Greenwich LifeSciences (GLSI) management is decisively developing a vaccine against breast cancer recurrence, effectively collaborating with physicians. However, the control structure is concentrated in the hands of insiders, which creates typical micro-cap risks. Investor success depends on the seamless completion of Phase III trials. The price-to-sales ratio reflects the business valuation dynamics, where the mark indicates the current valuation level relative to revenue.

greenwichlifesciences.com (GLSI) Price-to-Revenue Ratio: for the period 07/04/2022 - 11/14/2026

Analytical breakdowns for Greenwich LifeSciences, Inc (GLSI)

- current quotes and average value forecast:

Market Price greenwichlifesciences.com|GLSI - Price Target Chart

- stock exchange capitalization data:

Market Value Greenwich LifeSciences, Inc|GLSI - Enterprise Value

- book capitalization indicators:

Book Value of One Share Greenwich LifeSciences|GLSI - Company Book Value|Market Value to Book Value greenwichlifesciences.com|GLSI - Company Total Assets

- debt obligations and liquidity statistics:

Debt to Capital Greenwich LifeSciences|GLSI - Long-Term Debt to Capital|Current Liabilities to Capital Greenwich LifeSciences Inc|GLSI - Company Debts|Debt to Book Value Ratio Greenwich LifeSciences, Inc|GLSI - Company Long-Term Liabilities|Company Current Liabilities Greenwich LifeSciences|Interim Coverage Ratio greenwichlifesciences.com

- earnings and market multiples details:

GLSI - Net Profit|Future Profit Greenwich LifeSciences|GLSI - P/E Multiple|Future Price to Earnings Multiple Greenwich LifeSciences Inc.|GLSI - Price/Earnings to Growth Multiple|Business Value to Operating Income Before Depreciation Greenwich LifeSciences, Inc|GLSI - Profit before payment of interest, taxes and amortization|Earnings per share for the last twelve months Greenwich LifeSciences|GLSI - Net earnings per share (EPS TTM)|Year-over-year net earnings per share change for the last twelve months greenwichlifesciences.com|GLSI - Earnings growth in current year|Net earnings per share change forecast for next year Greenwich LifeSciences

- total revenue and sales volume data:

GLSI - Revenue and Sales Volume|Company Expected Sales Volume greenwichlifesciences.com|GLSI - Price-to-Revenue Ratio|Market Cap to Expected Sales Ratio Greenwich LifeSciences, Inc

Fundamental company analysis:greenwichlifesciences.com (GLSI)

Mass-produced product of Greenwich LifeSciences, Inc.

To minimize risks, it is crucial for investors to monitor asset revaluation by using the price-to-sales chart as a tool to measure the value of each unit of sales. High-tech bio-logistics and cold chain control ensure the operational stability of Greenwich LifeSciences (GLSI), allowing the P/S trend to be interpreted as an indicator of market confidence in the fundamental reliability of the pharmaceutical business.

Who Greenwich LifeSciences competes with

OLMA - Price to Sales|Price-to-Revenue Ratio Puma Biotechnology, Inc. PBYI|Market Capitalization-to-Revenue Ratio ZNTL|MacroGenics Corp - P/S Multiple|Price-to-Revenue Multiple Plus Therapeutics, Inc. (PSTV)|processapharmaceuticals.com (PCSA) - Price-to-Revenue Ratio|Eagle Pharmaceuticals, Inc. - Market Capitalization-to-Revenue Ratio